Dokument-ID Dokumenttyp Verfasser/Autoren Herausgeber Haupttitel Abstract Auflage Verlagsort Verlag Erscheinungsjahr Seitenzahl Schriftenreihe Titel Schriftenreihe Bandzahl ISBN Quelle der Hochschulschrift Konferenzname Quelle:Titel Quelle:Jahrgang Quelle:Heftnummer Quelle:Erste Seite Quelle:Letzte Seite URN DOI Abteilungen OPUS4-23560 Wissenschaftlicher Artikel Hartrampf, Philipp E.; Petritsch, Bernhard; Buck, Andreas K.; Serfling, Sebastian E. Pitfalls in PSMA-PET/CT: Intensive bone-marrow uptake in a case with polycythaemia vera No abstract available. 2020 1669–1670 European Journal of Nuclear Medicine and Molecular Imaging 48 urn:nbn:de:bvb:20-opus-235608 10.1007/s00259-020-05072-7 Klinik und Poliklinik für Nuklearmedizin OPUS4-12220 Wissenschaftlicher Artikel Soehnlein, Oliver; Drechsler, Maik; Döring, Yvonne; Lievens, Dirk; Hartwig, Helene; Kemmerich, Klaus; Ortega-Gómez, Almudena; Mandl, Manuela; Vijayan, Santosh; Projahn, Delia; Garlichs, Christoph D.; Koenen, Rory R.; Hristov, Mihail; Lutgens, Esther; Zernecke, Alma; Weber, Christian Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes We used a novel approach of cytostatically induced leucocyte depletion and subsequent reconstitution with leucocytes deprived of classical \((inflammatory/Gr1^{hi})\) or non-classical \((resident/Gr1^{lo})\) monocytes to dissect their differential role in atheroprogression under high-fat diet (HFD). Apolipoprotein E-deficient \((Apoe^{-/-})\) mice lacking classical but not non-classical monocytes displayed reduced lesion size and macrophage and apoptotic cell content. Conversely, HFD induced a selective expansion of classical monocytes in blood and bone marrow. Increased CXCL1 levels accompanied by higher expression of its receptor CXCR2 on classical monocytes and inhibition of monocytosis by CXCL1-neutralization indicated a preferential role for the CXCL1/CXCR2 axis in mobilizing classical monocytes during hypercholesterolemia. Studies correlating circulating and lesional classical monocytes in gene-deficient \(Apoe^{-/-}\) mice, adoptive transfer of gene-deficient cells and pharmacological modulation during intravital microscopy of the carotid artery revealed a crucial function of CCR1 and CCR5 but not CCR2 or \(CX_3CR1\) in classical monocyte recruitment to atherosclerotic vessels. Collectively, these data establish the impact of classical monocytes on atheroprogression, identify a sequential role of CXCL1 in their mobilization and CCR1/CCR5 in their recruitment. 2013 471-481 EMBO Molecular Medicine 5 urn:nbn:de:bvb:20-opus-122204 10.1002/emmm.201201717 Rudolf-Virchow-Zentrum OPUS4-11759 Wissenschaftlicher Artikel Giordano, Rosaria; Canesi, Margherita; Isalberti, Maurizio; Isaias, Ioannis Ugo; Montemurro, Tiziana; Viganň, Mariele; Montelatici, Elisa; Boldrin, Valentina; Benti, Riccardo; Cortelezzi, Agostino; Fracchiolla, Nicola; Lazzari, Lorenza; Pezzoli, Gianni Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study Background: Progressive Supranuclear Palsy (PSP) is a sporadic and progressive neurodegenerative disease which belongs to the family of tauopathies and involves both cortical and subcortical structures. No effective therapy is to date available. Methods/design: Autologous bone marrow (BM) mesenchymal stem cells (MSC) from patients affected by different type of parkinsonisms have shown their ability to improve the dopaminergic function in preclinical and clinical models. It is also possible to isolate and expand MSC from the BM of PSP patients with the same proliferation rate and immuphenotypic profile as MSC from healthy donors. BM MSC can be efficiently delivered to the affected brain regions of PSP patients where they can exert their beneficial effects through different mechanisms including the secretion of neurotrophic factors. Here we propose a randomized, placebo-controlled, double-blind phase I clinical trial in patients affected by PSP with MSC delivered via intra-arterial injection. Discussion: To our knowledge, this is the first clinical trial to be applied in a no-option parkinsonism that aims to test the safety and to exploit the properties of autologous mesenchymal stem cells in reducing disease progression. The study has been designed to test the safety of this " first-in-man" approach and to preliminarily explore its efficacy by excluding the placebo effect. Trial registration: NCT01824121 2014 Journal of Translational Medicine 12 14 urn:nbn:de:bvb:20-opus-117594 10.1186/1479-5876-12-14 Neurologische Klinik und Poliklinik